CTI BioPharma (CTIC) Receives Fast Track FDA Status

CTI BioPharma Corp (CTIC) received FDA Fast Track Designation for Pacritinib Wednesday night and the stock is on fire this morning. Shares of the biopharma company are higher by 4% to $2.54 in early pre market trading. The Seattle, Washington – based company announced that pacritinib, an oral tyrosine kinase inhibitor drug candidate with dual […] View the full post at: CTI BioPharma (CTIC) Receives Fast Track FDA Status No related posts.